Gathering data on hepatomiR for liver disease outcomes
Assessment of a hepatomiR Cut-off for Predicting Specific Hepatic Decompensation Events in Advanced Chronic Liver Disease
This study is trying to see how a new test for liver disease can help doctors understand and predict serious problems in patients with chronic liver issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 156 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Karl Landsteiner University of Health Sciences Academic / other |
| Locations | 1 site (Sankt Pölten, Lower Austria) |
| Trial ID | NCT06432582 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect data on hepatomiR, a CE-certified test designed to assess liver-related outcomes in patients with chronic liver disease. The focus is on defining a cut-off for specific decompensation events such as ascites, variceal hemorrhage, and hepatic encephalopathy. By analyzing these data, the study seeks to enhance the understanding of factors that contribute to liver decompensation, which could inform future risk management and therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with chronic liver disease lasting more than six months.
Not a fit: Patients with primary hepatic malignancies or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve risk assessment and management strategies for patients with chronic liver disease.
How similar studies have performed: While this approach is based on existing tests, the specific application of hepatomiR in this context is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Chronic liver disease (more than 6 months) * LSM ≥ 10 kPa * Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten * Signed patient consent form Exclusion Criteria: * Age older than 18 years * Pregnancy * Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and/or extrahepatic spread
Where this trial is running
Sankt Pölten, Lower Austria
- University Hospital St. Pölten — Sankt Pölten, Lower Austria, Austria (Recruiting)
Study contacts
- Principal investigator: Andreas Maieron, PD Dr. — Karl Landsteiner University of Health Sciences
- Study coordinator: Lukas Erhart, Mag. Dr.
- Email: lukas.erhart@stpoelten.lknoe.at
- Phone: 00432742900412311
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.